Current attitudes for therapy of febrile neutropenia with consideration to cost-effectiveness.
Febrile neutropenia is a changing syndrome which requires periodic updates as our armamentarium against this condition improves, and the characteristics of the pathogens change. In addition, cost of therapy has become a major issue when designing therapeutic strategies. This article reviews the basis of the current therapeutic approaches to febrile neutropenia, and this information is used to propose an algorithm for the management of this condition taking into consideration, in addition to these medical aspects, cost-effectiveness.
Service de Médecine, H.J. Tagnon, Institut Jules Bordet, Brussells, Belgium.
J
J
Klastersky
D003362:Cost-Benefit Analysis; D004358:Drug Therapy / Q000191:economics; D004471:Economics, Nursing; D005334:Fever / Q000188:drug therapy* / Q000191:economics* / Q000209:etiology; D016905:Gram-Negative Bacterial Infections / Q000150:complications / Q000188:drug therapy / Q000191:economics; D016908:Gram-Positive Bacterial Infections / Q000150:complications / Q000188:drug therapy / Q000191:economics; D006760:Hospitalization / Q000191:economics; D006801:Humans; D007902:Length of Stay; D009503:Neutropenia / Q000150:complications / Q000188:drug therapy* / Q000191:economics*